Investment Thesis
Day One Biopharmaceuticals is a pre-profitability biotech company with strong revenue growth (+20.6% YoY) but severely negative profitability metrics including -67.8% net margin and -$104.1M free cash flow. Despite solid liquidity (8.02x current ratio) and $197.1M cash, the company is burning cash rapidly and will need additional capital or significantly accelerated revenue growth to reach sustainability.
Strengths
- Strong revenue growth of 20.6% year-over-year demonstrates market traction and commercial progress
- Excellent liquidity position with 8.02x current ratio and $197.1M cash provides runway for operations
- Low leverage with 0.00x debt-to-equity ratio and minimal long-term debt reduces financial risk
- Significant stockholders' equity of $441.2M provides substantial cushion
Risks
- Severe operating losses of -$127.8M with -80.8% operating margin indicate core business is not profitable at scale
- Negative free cash flow of -$104.1M annually means cash runway is limited; at current burn rate, cash depletes within 1.9 years
- Net losses widening with -$107.3M net income suggests inability to control costs despite revenue growth
- Pre-profitability biotech model carries inherent R&D risk and requires sustained access to capital markets
Key Metrics to Watch
- Operating cash flow trend and path to operating profitability
- Revenue growth sustainability and gross margin expansion as product mix matures
- Cash burn rate and months of cash runway remaining
- Operating expense ratio relative to revenue and cost control improvements
Financial Metrics
Revenue
158.2M
Net Income
-107.3M
EPS (Diluted)
$-1.04
Free Cash Flow
-104.1M
Total Assets
507.8M
Cash
197.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-80.8%
Net Margin
-67.8%
ROE
-24.3%
ROA
-21.1%
FCF Margin
-65.8%
Balance Sheet & Liquidity
Current Ratio
8.02x
Quick Ratio
7.91x
Debt/Equity
0.00x
Debt/Assets
13.1%
Interest Coverage
-6,723.68x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T09:28:11.318100 |
Data as of: 2025-12-31 |
Powered by Claude AI